Search research articles
Contact Us
Filters
Showing results (361-370 of 445) with videos related to
Page
of 45
Sort By:
Gastroenterology
|
July 9, 2025
Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation
Pornlada Likasitwatanakul, Zhixin Li, Paul Doan, et al.
Biorxiv : the Preprint Server for Biology
|
December 23, 2024
Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation
Pornlada Likasitwatanakul, Zhixin Li, Paul Doan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial
James M Cleary, Christoph Springfeld, Dirk Arnold, et al.
BMC Cancer
|
July 15, 2016
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer
James M Cleary, Harvey J Mamon, Jackie Szymonifka, et al.
BJC Reports
|
February 27, 2025
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
J Randolph Hecht, Jean-Marie Michot, David Bajor, et al.
JCO Precision Oncology
|
April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
Margherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
NPJ Precision Oncology
|
May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology
|
April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
Page
of 45
Search research articles
Search
Showing results (361-370 of 445) with videos related to
Sort By:
Page
of 45
Gastroenterology
|
July 9, 2025
Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation
Pornlada Likasitwatanakul, Zhixin Li, Paul Doan, et al.
Biorxiv : the Preprint Server for Biology
|
December 23, 2024
Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation
Pornlada Likasitwatanakul, Zhixin Li, Paul Doan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial
James M Cleary, Christoph Springfeld, Dirk Arnold, et al.
BMC Cancer
|
July 15, 2016
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer
James M Cleary, Harvey J Mamon, Jackie Szymonifka, et al.
BJC Reports
|
February 27, 2025
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
J Randolph Hecht, Jean-Marie Michot, David Bajor, et al.
JCO Precision Oncology
|
April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
Margherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
NPJ Precision Oncology
|
May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology
|
April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
Page
of 45